On July 8, 2021, Shanghai-Mabwell (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Mabwell"), an innovative biopharmaceutical company with a whole industrial chain, announced today that it would cooperate with Fudan University Shanghai Cancer Center (hereinafter referred to as "FUSCC") to explore cooperation in the field of oncology and sign a strategic cooperation agreement. Both parties will cooperate deeply in scientific research cooperation, personnel training, hospital management, platform construction, etc. by exerting their respective advantages and resources based on the patients' requirements in order to promote the clinical and translational medicine studies in the field of oncology and boost the innovative development of the pharmaceutical industry in China to accelerated benefit to more cancer patients in China. Datao Liu, PhD, Founder and CEO of Mabwell, and Professor Xiaomao Guo, President of FUSCC signed the strategic agreement as representatives under witness of representatives of Mabwell and FUSCC.

Contracting Ceremony of Clinical Study Strategic Cooperation

According to the cooperation agreement, both parties will cooperate in early and key clinical registration studies, real-world data, etc. FUSCC will give priority to review and start-up provided that the internal standard procedures are met, provides suggestions for Mabwell in early R&D strategies for new targets and continuous development of innovative products, and gives Mabwell supporting in smooth, rapid and high-quality clinical trials. In addition, both parties will establish a talent exchange and cooperation training platform to provide training on industry dynamics, advanced international treatment and clinical trial management concepts.

Datao Liu, PhD, Founder and CEO of Mabwell, said: "I am pleased to have a strategic partnership with Fudan University Shanghai Cancer Center. Mabwell has an advanced anti-tumor drug development platform, with the mission of exploring life and benefiting health; FUSCC has a deep accumulation of subjects and rich experience in clinical trials. We believe that in the future, both of us will exert our respective advantages and resources to jointly promote clinical and translational medicine studies of new oncology drugs, improve the precision treatment ability, and allow more patients to benefit from high-quality biotherapy".

Jiong Wu, Vice President of FUSCC, said: "I am pleased to be able to establish a strategic partnership with Mabwell. I believe that today is a new start for both FUSCC and Mabwell, and we will make a new breakthrough in clinical studies, especially for malignant tumors. I believe that with this cooperation, we will work together to promote the application of new technologies and new concepts in the clinical practice, so as to better serve patients and all people".

About FUSCC

Fudan University Shanghai Cancer Center (FUSCC) is one of the budget management units under the National Health Commission, and a joint trustee established by the Ministry of Education, the National Health Commission and the Shanghai Municipal People's Government. Since its establishment on March 1, 1931 as the earliest specialized cancer hospital in China, FUSCC has now developed to be a Grade-A tertiary hospital engaged in the integration of clinical practice, medical education, oncologic research and cancer prevention.